Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin

Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin

Autor Mori, R. C. T. Google Scholar
Hirabara, S. M. Google Scholar
Hirata, A. E. Autor UNIFESP Google Scholar
Okamoto, M. M. Google Scholar
Machado, U. F. Google Scholar
Instituição Universidade de São Paulo (USP)
Universidade Federal de São Paulo (UNIFESP)
Resumo Aim: Glimepiride, a low-potency insulin secretagogue, is as efficient on glycaemic control as other sulphonylureas, suggesting an additional insulin-sensitizer role. the aim of the present study was to confirm the insulin-sensitizer role of glimepiride and to show extra-pancreatic effects of the drug.Methods: Three-month-old monosodium glutamate (MSG)-induced obese insulin-resistant rats were treated (OG) or not treated (O) with glimepiride for 4 weeks and compared with age-matched non-obese rats (C). Insulin sensitivity in whole body, glucose transporter 4 (GLUT4) protein content, glucose uptake and glycogen synthesis in oxidative skeletal muscle and phospho-glycogen synthase kinase (p-GSK3) and glycogen content in liver were analysed.Results: Insulin sensitivity, analysed by the insulin tolerance test, was 30% lower in O than in C rats (p < 0.05), and OG rats recovered this parameter (p < 0.05). in oxidative muscle, glimepiride increased the GLUT4 protein content (50%, p < 0.001) and recovered the obesity-induced reduction (similar to 20%) of the in vitro insulin-stimulated glucose uptake and incorporation into glycogen. in liver, glimepiride increased p-GSK3 (p < 0.01) and glycogen (p < 0.05) contents.Conclusion: the increased GLUT4 protein expression and glucose utilization in oxidative muscle and the increased insulin sensitivity and glycogen storage in liver evidence the insulin-sensitizer effect of glimepiride, which must be important to enable the glimepiride drug to promote an efficient glycaemic control.
Assunto glimepiride
insulin resistance
skeletal muscle
Idioma Inglês
Data 2008-07-01
Publicado em Diabetes Obesity & Metabolism. Malden: Wiley-Blackwell, v. 10, n. 7, p. 596-U5, 2008.
ISSN 1462-8902 (Sherpa/Romeo, fator de impacto)
Editor Wiley-Blackwell
Extensão 596-U5
Direito de acesso Acesso restrito
Tipo Artigo
Web of Science WOS:000256841700009

Mostrar registro completo

Arquivos deste item

Arquivos Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item aparece na(s) seguinte(s) coleção(s)